Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma

[1] Kumar SK(2004)Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 867-874

[2] Therneau TM(2007)Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 6383-6391

[3] Gertz MA(2009)Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges Cancer Lett 280 233-41

[4] Demo SD(2008)CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 14 2775-84

[5] Kirk CJ(2015)Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma Haematologica 100 670-6

[6] Aujay MA(2015)Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma Blood 126 2284-90

[7] Atadja P(2014)Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy Leukemia 28 1529-36

[8] Hsi ED(2013)Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Clin Cancer Res 19 248-56

[9] Steinle R(2015)Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma J Clin Oncol 33( 732-9

[10] Balasa B(2015)Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N Engl J Med 372 14-52

[1] Kumar SK(2004)Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 867-874

[2] Therneau TM(2007)Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 6383-6391

[3] Gertz MA(2009)Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges Cancer Lett 280 233-41

[4] Demo SD(2008)CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 14 2775-84

[5] Kirk CJ(2015)Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma Haematologica 100 670-6

[6] Aujay MA(2015)Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma Blood 126 2284-90

[7] Atadja P(2014)Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy Leukemia 28 1529-36

[8] Hsi ED(2013)Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Clin Cancer Res 19 248-56

[9] Steinle R(2015)Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma J Clin Oncol 33( 732-9

[10] Balasa B(2015)Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N Engl J Med 372 14-52